Horizon Therapeutics (HZNP) Tops Q4 EPS by 6c

Horizon Therapeutics (NASDAQ: HZNP) reported Q4 EPS of $1.41, $0.06 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $995.87 million.

GUIDANCE:

Horizon Therapeutics sees FY2022 revenue of $3.9-4 billion, versus the consensus of $3.91 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Accuray (ARAY) Tops Q4 EPS by 1c
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance